NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
Hyundai Motor Shares Slide After Trump Signals Higher U.S. Tariffs on South Korean Goods 
Ford and GM Near Financing Deal to Support First Brands Group During Bankruptcy 
Noble Corporation Secures $1.3 Billion in New Contracts, Strengthening Offshore Drilling Backlog 
Micron to Expand Memory Chip Manufacturing Capacity in Singapore Amid Global Shortage 
Baker Hughes Reports 11% Rise in Q4 Adjusted Profit Driven by LNG Demand 
Citigroup Faces Lawsuit Over Alleged Sexual Harassment by Top Wealth Executive 
Trump Lawsuit Against JPMorgan Signals Rising Tensions Between Wall Street and the White House 
Shell Plc Downgraded by RBC as Market Headwinds Pressure Valuation 
Microsoft Wins Approval to Build 15 New Data Centers in Wisconsin 
LVMH Succession Uncertainty Raises Governance Concerns Among Shareholders 
Ryanair Profit Slumps in Q3 After Italy Antitrust Fine Despite Revenue Growth 
Trump Administration Takes Stake in USA Rare Earth to Boost U.S. Critical Minerals Supply 
Alibaba-Backed Moonshot AI Unveils Kimi K2.5 to Challenge China’s AI Rivals 
Samsung Set to Begin HBM4 Production for Nvidia and AMD 
Tesla Loses Ground in Europe as BYD Accelerates EV Market Share in 2025 
WALTHAM, Mass., May 15, 2017 -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS), a fully integrated science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, announced that on May 15, 2017, the Company's Board of Directors granted Jose (Pepe) Carmona, the Company’s Chief Financial Officer, an option to purchase 125,000 shares of the Company's common stock with a per share exercise price of $34.96, the closing trading price of the Company’s common stock on the NASDAQ Global Market on the grant date of May 15, 2017. The option vests 25% on the first anniversary of the grant date, with the remaining 75% to vest in monthly installments over the three years thereafter, and has a ten-year term. The stock option was granted pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules for equity grants to induce Mr. Carmona to enter into employment with the Company.
About Radius
Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius' lead product, TYMLOS™ (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe. The Radius clinical pipeline includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Radius' RAD140, a non-steroidal, selective androgen receptor modulator (SARM), is under investigation for potential use in hormone receptor positive breast cancer. For more information, please visit www.radiuspharm.com.
Investor Relations Contact: Barbara Ryan Email: [email protected] Phone: 203-274-2825 Media Contact: Lori Gorski Email: [email protected] Phone: 617-551-4096
